Chongqing Haifu Technology

What Chongqing Haifu Technology does

Chongqing Haifu Medical Technology Co., Ltd., founded in 1999 and headquartered in Beibei District, Chongqing, China, is a privately held manufacturer of non-invasive High-Intensity Focused Ultrasound (HIFU) therapeutic systems. The company operates an integrated model combining R&D, manufacturing, clinical research, and physician training, anchored by a long-standing partnership with Chongqing Medical University and the National Engineering Research Center of Ultrasound Medicine. Its core platform, the JC series (JC, JC200, JC200D, JC300), uses focused ultrasound mechanical, thermal, and cavitation effects to induce coagulative necrosis in target tissue without incision, bleeding, or radiation, applied across liver, pancreatic, breast, and bone tumors as well as benign indications such as uterine fibroids and adenomyosis. Complementing the JC platform are specialized therapeutic devices (Seapostar/CZF for gynecology, Seapopinna/CZB for rhinitis, Seapoconch/CZG300 for arthritis, Seapocare/CKC100 for postpartum uterine involution, and LCA200 for chronic soft tissue injury), plus the next-generation FUAS 3.0 platform extending into brain disorders.

The company sells directly to hospitals and medical institutions via enterprise field sales, bundled with 1-5 year service contracts, software upgrades, physician training, and a global telemedicine service center. Go-to-market combines direct hospital sales with a HIFU Treatment Center model in which partner hospitals host dedicated suites that also serve as regional training hubs. Pricing is quote-based, with high-end MRI-guided HIFU platforms reported to exceed USD 1 million. Products have been installed in 3,000+ medical institutions across China and 80+ hospitals abroad across 36 countries, with regulatory approvals in 40+ jurisdictions including EU CE (2005, first in class for extracorporeal ultrasound tumor ablation), China NMPA, and Russian, Korean, Argentine, Saudi, Malaysian, and Egyptian certifications. Approximately 350,000 patients have been treated with HAIFU systems and 3,000+ physicians from 135 countries have been trained through the company's Clinical Training Center.

Revenue model rests on three streams: hardware sales of HIFU systems and therapeutic devices, recurring service and maintenance contracts, and professional training/education services. Strategic positioning is reinforced by inclusion of HIFU therapy in international clinical guidelines (FIGO 2025, NICE 2019, ACOG, SOGC, KSOG), the Focused Ultrasound Foundation's 2022 Clinical Application Award to Prof. Zhibiao Wang, and the FUSF Center of Excellence designation granted to Chongqing Haifu Hospital in 2025 (the first in China). The company's wholly owned subsidiary Chongqing Haifu Hospital functions both as a flagship treatment facility and as a credentialed clinical-research anchor for the wider HIFU network.

Name

Chongqing Haifu Technology

Legal name

Chongqing Haifu Medical Technology Co., Ltd.

Website

https://haifumedical.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Chongqing Haifu Medical Technology is a Chinese manufacturer of non-invasive High-Intensity Focused Ultrasound (HIFU) therapeutic systems used by hospitals worldwide for ablation of solid tumors (liver, pancreatic, breast, bone) and treatment of benign conditions such as uterine fibroids and adenomyosis.

Ownership category

akta.pro rank

Product category

Therapeutic Ultrasound Medical Equipment

NAICS

Medical Equipment and Supplies Manufacturing (3391), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Gastrointestinal Oncology (HLAKAFAK)

Keywords

• Focused ultrasound ablation
• HIFU tumor therapy
• Non-invasive medical devices
• Therapeutic ultrasound systems
• Oncology treatment equipment

Headquarters

HQ city

Chongqing

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

1. HIFU Medical Equipment Sales: Sale of high-intensity focused ultrasound tumor therapeutic systems and related medical devices to hospitals and healthcare institutions worldwide. Equipment includes JC300, JC200, JC200D, JC models and specialized therapeutic devices for various applications.
2. Service and Maintenance Contracts: Ongoing technical support, clinical service via telemedicine center, engineering service via telemedicine center, and software upgrades provided as part of equipment contracts ranging from 1 to 5 years.
3. Training and Education Services: HIFU doctor training, clinical support, and professional education services for physicians from around the world through the Clinical Training Center and global training facilities.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Chongqing Haifu Technology manufactures and sells High-Intensity Focused Ultrasound (HIFU) tumor therapeutic systems that enable non-invasive, extracorporeal ablation of solid tumors and benign diseases without incisions, bleeding, or radiation. The core product portfolio centers on the JC Series (JC, JC200, JC200D, JC300) for oncology and gynecology applications, supplemented by specialized therapeutic devices for rhinitis, arthritis, uterine involution, and chronic soft tissue injury. Sales are bundled with multi-year maintenance contracts, physician training, and global clinical support via telemedicine center.

Product overview

Chongqing Haifu Medical Technology offers a comprehensive portfolio of focused ultrasound therapeutic systems centered around the JC Series (JC, JC200, JC200D, JC300) as the core platform for non-invasive tumor ablation. The JC Series systems use High-Intensity Focused Ultrasound (HIFU) technology for treatment of solid tumors (liver, pancreatic, breast, bone cancers, uterine fibroids, adenomyosis) without incisions, bleeding, or radiation. Complementing the JC platform are specialized therapeutic devices including the Seapostar (CZF) for gynecology, Seapopinna (CZB) for rhinitis, Seapoconch (CZG300) for arthritis, Seapocare (CKC100) for postpartum uterine involution, and LCA200 for pain management. The company also maintains a global telemedicine center providing remote training and clinical support. The product ecosystem is designed for organ-preserving, non-invasive treatments across oncology and benign disease applications.

Differentiator

Problem solved

Functional benefit

Brands

• Seapocare: Ultrasound therapeutic device brand including CKC100 for uterus involution
• Seapopinna
• Seapostar
• HAIFU Knife
• Seapostar

Products and services

• JC300 Focused Ultrasound Tumor Therapeutic System Flagship non-invasive focused ultrasound system for extracorporeal ablation treatment of malignant and benign tumors. Used by hospitals and oncology centers to deliver tumor ablation without incisions, bleeding, or radiation.
• JC200 Focused Ultrasound Tumor Therapeutic System Non-invasive, extracorporeal ultrasound ablation treatment system for solid tumors including liver, kidney, breast, bone, pancreatic cancers, uterine fibroids, and adenomyosis. CE marked in 2007.
• JC Focused Ultrasound Tumor Therapeutic System Original HAIFU focused ultrasound tumor therapeutic system for non-invasive treatment of solid tumors including liver cancer, breast cancer, bone tumors, and benign tumors such as uterine fibroids. The first CE-marked HIFU tumor ablation device in Europe.
• JC200D Focused Ultrasound Tumor Therapeutic System (Gynecology) Specialized focused ultrasound system dedicated to non-invasive treatment of benign gynecologic tumors such as uterine fibroids and adenomyosis, preserving uterus and sexual function.
• CZF (Seapostar) Ultrasound Therapeutic Device for Gynecology Ultrasound therapeutic device for treatment of chronic cervicitis, non-neoplastic epithelial disorders of vulva, and condyloma acuminatum. Used by gynecology departments and women's health centers.
• CZB (Seapopinna) Ultrasound Therapeutic Device for Rhinitis Non-invasive ultrasound device for treatment of allergic rhinitis, protecting nasal cavity structure without bleeding or adhesion. Used by ENT departments and allergy clinics.
• CZG300 (Seapoconch) Ultrasound Therapeutic Device for Arthritis Ultrasound therapeutic device using low-intensity pulsed ultrasound to treat arthritis by promoting analgesic substance release and cartilage repair. Used by rehabilitation and rheumatology departments.
• CKC100 (Seapocare) Ultrasound Therapeutic Device for Involution of Uterus Ultrasound therapeutic device for involution of uterus using low-intensity pulsed ultrasound to stimulate rhythmic contraction of uterine smooth muscle. Used in postpartum care.
• LCA200 Ultrasound Therapeutic Device for Ashi Points Ultrasound device for treatment of chronic soft tissue injury on neck-shoulder, abdomen and limbs, using focused ultrasound to mimic acupuncture effects and promote tissue repair. Used in pain management clinics.

Quantifiable outcome

• 350,000+ patients treated worldwide with non-invasive, organ-preserving procedures
• +5 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• International Society of Minimally Invasive and Virtual Surgery (ISMIVS)coreStrategic or Co-development Partner · 21 June 2025Co-organizer of Yangtze Forum of Minimally and Non-Invasive Medicine. ISMIVS President Prof. Philippe Descamps led FIGO expert group that included HIFU in guidelines. Joint efforts in promoting global adoption of focused ultrasound technology.
• Focused Ultrasound Foundation (FUSF)coreStrategic or Co-development Partner · 1 January 2025Designated Chongqing Haifu Hospital as 13th global Center of Excellence (first in China). Foundation Chairman Dr. Neal F. Kassell praised Haifu as 'undoubtedly a leading manufacturer.' Expanded collaboration in clinical research, Centers of Excellence development, and global education and training.
• SiemenscoreStrategic or Co-development Partner · 1 August 2005Joint development of MRI-guided Focused Ultrasound Tumor Therapeutic System (Model JM). Collaboration combining Siemens' MRI technology with Haifu's HIFU expertise for enhanced treatment precision and imaging guidance.
• Chongqing Medical UniversitycoreStrategic or Co-development PartnerLong-term academic partnership integrating manufacturing, marketing, R&D, and education. Collaborates with university and its affiliated hospitals for clinical research, technology development, and physician training. Co-founded National Engineering Research Center of Ultrasound Medicine.
• University of Oxford (UK)coreStrategic or Co-development PartnerEstablished academic relationship with Churchill Hospital for HIFU clinical trials. First installation of Chinese large-scale high-end medical device in developed market (2002). Oxford HIFU Unit established in 2002 under Prof. David Cranston, achieving NICE guideline inclusion in 2019.
• European Institute of Oncology (Italy)coreStrategic or Co-development PartnerAcademic partnership for clinical research and HIFU therapy development in oncology applications.
• Florence University (Italy)minorStrategic or Co-development PartnerAcademic collaboration for research and development in focused ultrasound technology.
• Bonn University (Germany)coreStrategic or Co-development PartnerHIFU Unit established in 2014, primarily focused on pancreatic cancer treatment. Published clinical outcomes in German Medical Association official journal. Demonstrated effectiveness in pain relief and survival improvement for pancreatic cancer patients.
• University of Hong KongcoreStrategic or Co-development PartnerAcademic partnership with Queen Mary Hospital for HIFU clinical applications and research.

Scale indicators9 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Insightec: Israel-based developer of ExAblate, an MRI-guided focused ultrasound platform for non-invasive ablation. Closest direct competitor in therapeutic HIFU for uterine fibroids and oncology, with strong US FDA-cleared footprint.
• Profound Medical Corp. Canada-based medical device company commercializing the TULSA-PRO system for MRI-guided transurethral ultrasound ablation of prostate tissue. Direct peer in therapeutic focused ultrasound, primarily in urologic oncology.
• EDAP TMS SA: France-based company offering Ablatherm and Focal One high-intensity focused ultrasound devices for prostate cancer. Competes in the same HIFU ablation category with established European and US regulatory clearances.
• Theraclion SA: France-based company developing echotherapy (focused ultrasound) systems for non-invasive treatment of thyroid nodules, breast fibroadenomas, and varicose veins. Direct peer in non-invasive ultrasound ablation of benign and malignant tumors.
• SonaCare Medical: US-based developer of the Sonablate high-intensity focused ultrasound system for prostate tissue ablation. Direct peer in HIFU ablation devices targeting urologic oncology and other solid tumors.

Broad incumbents

• Philips Healthcare: Global medical imaging and interventional equipment leader. Broad incumbent in image-guided therapy, including partnerships and internal programs around focused ultrasound and minimally invasive therapy; competes at hospital-system level for capital budgets.
• Siemens Healthineers: Global medical technology leader. Has been an HAIFU partner since 2005 for MRI-guided HIFU (Model JM). Broad incumbent in diagnostic imaging and image-guided interventions, serving overlapping hospital customers.
• GE HealthCare: Global medical imaging and ultrasound equipment leader. Competes in the broader image-guided therapy market and supplies ultrasound platforms used to guide HIFU procedures at many HAIFU-installed sites.

Emerging players

• Alpinion Medical Systems: South Korea-based developer of therapeutic and diagnostic ultrasound systems, including HIFU platforms. Emerging peer in Asian markets with overlapping oncology and aesthetic applications.
• HistoSonics: US-based company developing histotripsy, a non-invasive focused-ultrasound-based platform for tissue destruction in liver and other oncology indications. Emerging player with a closely related technological approach competing for the same hospital therapeutic-ultrasound category.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCcP2OKws-ZTT-7Vwe5OJahQ
• Facebookfacebook.com/haifumedical
• LinkedInlinkedin.com/company/3111586/admin

Compliance21 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chongqing Haifu Technology